For adults with moderate to severe Crohn's disease in whom TNF blockers did not work well, or after a different injection or pill (systemic therapy) when TNF blockers are not recommended by your healthcare provider

RINVOQ

Results

RINVOQ results that won't back down

RINVOQ was proven to help deliver results in two 12-week clinical trials in people with moderate to severe Crohn's. Those who achieved clinical response at 12 weeks entered a maintenance trial, where RINVOQ helped deliver results at 1 year. See details below:

How soon did people feel symptom relief?

2 weeks — RINVOQ helped people experience rapid symptom relief, including less abdominal pain and fewer bowel movements

12 weeks — RINVOQ helped significantly reduce fatigue

Rapid symptom relief* at 2 weeks

Graph showing the percentage of people who experienced rapid symptom relief at 2 weeks. Results are 14% for placebo (n=146) and 37% for RINVOQ 45mg (n=273) from Study 1. Results are 24% for placebo (n=143) and 37% for RINVOQ 45mg (n=295) from Study 2.

*Including less abdominal pain and fewer bowel movements.

How soon could a doctor see visible repair of the intestinal lining?

12 weeks and 1 year — RINVOQ helped deliver visible repair† of the intestinal lining

†Areas visually assessed on endoscopy may not represent total resolution or repair of the entire intestinal lining or deeper bowel layers.

Visible repair† of the intestinal lining at 12 weeks

HUMIRA 40 mg every other week + methotrexate (n=246)

Graph showing the percentage of people who experienced visible repair of the intestinal lining at 12 weeks. Results are 3% for placebo (n=146) and 34% for RINVOQ 45mg (n=273) from Study 1. Results are 13% for placebo (n=143) and 46% for RINVOQ 45mg (n=295) from Study 2.

Visible repair† of the intestinal lining at 1 year

Results from 343 patients who achieved clinical response‡

Graph showing visible repair of the intestinal lining at 1 year, among patients who achieved clinical response at 12 weeks. Results are 7% for placebo (n=111), 28% for RINVOQ 15mg (n=113), and 41% for RINVOQ 30mg (n=119) from Study 3.

‡Defined as a reduction of CDAI of at least 100 points from baseline after 12 weeks of treatment with RINVOQ.

When did people experience remission, meaning few to no Crohn’s symptoms?

12 weeks and 1 year — RINVOQ helped people achieve remission in Crohn’s

RINVOQ also helped deliver early remission without steroids at 12 weeks, and lasting steroid-free remission at 1 year

Steroid-free remission at 12 weeks

Graph showing the percentage of people who experienced steroid-free remission at 12 weeks. Results are 11% for placebo (n=53) and 30% for RINVOQ 45mg (n=96) from Study 1. Results are 13% for placebo (n=54) and 40% for RINVOQ 45mg (n=108) from Study 2.

Steroid-free remission at 1 year

Results from 343 patients who achieved clinical response‡

Graph showing the percentage of people who experienced steroid-free remission at 1 year. Results are 14% for placebo (n=111), 42% for RINVOQ 15mg (n=113), and 53% for RINVOQ 30mg (n=119) from Study 3.

‡Defined as a reduction of CDAI of at least 100 points from baseline after 12 weeks of treatment with RINVOQ.

What long-term results are available for RINVOQ?

4 years§   — Some people taking RINVOQ for Crohn’s experienced visible repair† of the intestinal lining

4 years§   — Some people taking RINVOQ for Crohn’s were in remission

§In the less strict study at 4 years, everyone knew RINVOQ was used, which may have increased results. Results measured in RINVOQ-treated patients who met clinical response (decrease of CDAI score by ≥100 points) at 12 weeks.

†Areas visually assessed on endoscopy may not represent total resolution or repair of the entire intestinal lining or deeper bowel layers.

Keep scrolling for safety considerations and real patient endoscopy images from RINVOQ clinical trials

Arrow Down

SAFETY CONSIDERATIONS

RINVOQ may cause serious side effects, including:

  • Serious infections. RINVOQ can lower ability to fight infections. Serious infections, some fatal, occurred, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses.
  • Increased risk of death in people age 50+ with at least 1 heart disease risk factor.
  • Cancer and immune system problems. Increased risk of some cancers, including lymphoma and skin. Current or past smokers have higher risk for lymphoma and lung cancer.
  • Increased risk of major cardiovascular events such as heart attack, stroke, or death in people 50+ with at least 1 heart disease risk factor, especially in current or past smokers.
  • Blood clots, some fatal, in veins of the legs or lungs and arteries. This occurred more often in people 50+ with at least 1 heart disease risk factor.
  • Serious allergic reactions. Do not take if allergic to RINVOQ or its ingredients.
  • Tears in the stomach or intestines; low blood sugar in people with diabetes; and changes in certain laboratory test results.

Learn more about these and the full Important Safety Information below. 

See what visible repair† of the intestinal lining in Crohn’s can look like

Real clinical trial patient endoscopy images

Adult patient with moderate to severe Crohn’s disease received RINVOQ 45 mg (induction) and 15 mg (maintenance), once daily. This patient achieved endoscopic remission at Week 12 and also at 1 year.

In clinical trials, some patients on RINVOQ experienced endoscopic remission at 12 weeks and 1 year. Results at 1 year were measured in RINVOQ-treated patients who met clinical response‡ at 12 weeks.

Individual results may vary.
Your doctor will decide which maintenance dose (15 mg or 30 mg) is right for you.

Endoscopic remission — Endoscopic remission in Crohn’s is achieved when your doctor sees little to no damage in the intestinal lining, characterized by mild to inactive disease as seen on endoscopy. 

Endoscopic remission — Endoscopic remission in Crohn’s is achieved when your doctor sees little to no damage in the intestinal lining, characterized by mild to inactive disease as seen on endoscopy. 

†Areas visually assessed on endoscopy may not represent total resolution or repair of the entire intestinal lining or deeper bowel layers.

‡Defined as a reduction of CDAI (CDAI = Crohn's Disease Activity Index) of at least 100 points from baseline after 12 weeks of treatment with RINVOQ.